Search

We describe adipose stromal/stem cells (ASCs) in the structural/functional context of the adipose tissue (AT) stem niche (adiponiche), including cell–cell interactions and the microenvironment, and emphasize findings obtained in humans and in lineage-tracing models. ASCs have distinctive markers, 'colors', and anatomical 'locations' which influence their functions. Each adiponiche component can become impaired, thereby contributing to the pathological AT alterations seen in obesity and metabolic diseases. We discuss adiposopathy with a focus on adiponiche dysfunction, and underline the mechanisms that control AT expansion and energy balance. Better understanding of adiponiche regulation and ASC features could help to identify therapeutic targets that favor weight loss and counteract weight regain, and also contribute to innovative strategies for regenerative medicine. ASCs have been analyzed in the structural/functional context of the adiponiche. The adiponiche consists of multiple cell types, the microenvironment, and their interactions that control ASC homeostasis. ASCs possess specific markers distinct characteristics that are associated with their anatomical 'location', and probably their 'color'. ASCs localize near to blood vessels and probably consist of many distinct subpopulations. Each adiponiche component can became dysregulated and can play a role in obesity and metabolic disease. [ABSTRACT FROM AUTHOR]

The article presents a case report of a 49-year old woman who was admitted with chronic renal failure and solicited opinions for further diagnosis. Family characterization indicated cases of retinitis pigmentosa, deafness, and nephropathy. The patient was found with genetic disorders and ciliopathies that impaired the kidney functions.

Background: Alström Syndrome (ALMS) is an extremely rare multiorgan disease caused by mutations in ALMS1. Dilated cardiomyopathy (DCM) is a common finding but only one series has been investigated by Cardiac Magnetic Resonance (CMR). Methods: Eight genetically proven ALMS patients (ages 11–41) underwent CMR performed by standard cine steady state, T1, T2 and late gadolinium enhancement (LGE) sequences. Ejection fraction (EF), Diastolic Volume (EDV) and Systolic Volume normalized for body surface area (ESV), and mass indices were determined, as well as EDV/Mass ratio, an index expressing the adequacy of cardiac mass to heart volume. Regional fibrosis was assessed by LGE; diffuse fibrosis was measured by a TI scout sequence acquired at 5, 10 and 15min after gadolinium by comparing inversion time values (TI) at null time in ALMS and control group. Results: In one patient severe DCM was present with diffuse LGE. There were seven cases without clinical DCM. In these patients, EF was at lower normal limits or slightly reduced and ESV index increased; six patients had decreased mass index and EDV/Mass ratio. Mild regional non ischemic fibrosis was detected by LGE in three cases; diffuse fibrosis was observed in all cases, as demonstrated by shorter TI values in ALMS in comparison with controls (5min: 152±12 vs 186±16, p 0.0002; 10min: 175±8 vs 204±18, p 0.0012; 15min: 193±9 vs 224±16, p 0.0002). Conclusions: Cardiac involvement in ALMS is characterized by progressive DCM, associated with systolic dysfunction, myocardial fibrosis and reduced myocardial mass. [ABSTRACT FROM AUTHOR]

Abstract: Kinetic studies were performed with various alkanamines as “substrate probes” of the properties of the active site of the human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1). We found that the enzyme–substrate recognition step is mainly controlled by apolar interactions and that a “good” substrate has a molecular structure containing a long aliphatic chain and a second positive charge at a distance greater than 12 Ǻ from the reactive amino group. In this context, we identified a novel substrate for the human SSAO/VAP-1, 1,12-diaminododecane (DIADO), which is characterised by the highest catalytic efficiency reported to date in comparison to the prototypic substrate benzylamine. Computational docking studies revealed the structural basis of this behaviour, highlighting the key role played by Lys393 in hindering substrate docking. Maximum SSAO/VAP-1 activity is reached at relatively low concentrations of DIADO (10–30μM), and, in these conditions, it has good selectivity: it is a good substrate of SSAO/VAP-1 but not of human adipocyte monoamine oxidases or pig kidney diamine oxidase. From these findings, it appears that DIADO can be used as a new substrate for human SSAO/VAP-1 to elicit glucose transport into adipocytes, and may consequently have potential pharmacological applications in the design of anti-diabetic agents. [Copyright &y& Elsevier]